Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables (2016 - 2025)

Historic Receivables for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $35.9 million.

  • OptimizeRx's Receivables rose 1119.74% to $35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 1119.74%. This contributed to the annual value of $41.5 million for FY2024, which is 207.18% down from last year.
  • OptimizeRx's Receivables amounted to $35.9 million in Q3 2025, which was up 1119.74% from $37.0 million recorded in Q2 2025.
  • OptimizeRx's Receivables' 5-year high stood at $42.3 million during Q4 2023, with a 5-year trough of $757218.0 in Q3 2021.
  • Over the past 5 years, OptimizeRx's median Receivables value was $20.8 million (recorded in 2023), while the average stood at $22.3 million.
  • As far as peak fluctuations go, OptimizeRx's Receivables tumbled by 9432.05% in 2021, and later skyrocketed by 225252.04% in 2022.
  • OptimizeRx's Receivables (Quarter) stood at $26.9 million in 2021, then fell by 4.36% to $25.7 million in 2022, then skyrocketed by 64.46% to $42.3 million in 2023, then decreased by 2.07% to $41.5 million in 2024, then decreased by 13.28% to $35.9 million in 2025.
  • Its Receivables stands at $35.9 million for Q3 2025, versus $37.0 million for Q2 2025 and $37.0 million for Q1 2025.